Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
about
Autism spectrum disorders: is mesenchymal stem cell personalized therapy the future?Methylphenidate for core and ADHD-like symptoms in children aged 6 to 18 years with autism spectrum disorders (ASDs)Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescentsHyperbaric oxygen therapy for autism spectrum disorder (ASD) in children and adultsOmega-3 fatty acids supplementation for autism spectrum disorders (ASD)Consensus paper: pathological role of the cerebellum in autismProgress of mesenchymal stem cell therapy for neural and retinal diseasesSystematic review of the properties of tools used to measure outcomes in anxiety intervention studies for children with autism spectrum disordersPsychiatric comorbidities in asperger syndrome and high functioning autism: diagnostic challengesASD: Psychopharmacologic Treatments and Neurophysiologic Underpinnings.Reducing ineffective practice: challenges in identifying low-value health care using Cochrane systematic reviews.Managing anxiety and depressive symptoms in adults with autism-spectrum disorders.MAOA, DBH, and SLC6A4 variants in CHARGE: a case-control study of autism spectrum disorders.High prescription drug use and associated costs among Medicaid-eligible children with autism spectrum disorders identified by a population-based surveillance networkInverse Effect of Fluoxetine on Medial Prefrontal Cortex Activation During Reward Reversal in ADHD and Autism.Pharmacologic treatment of repetitive behaviors in autism spectrum disorders: evidence of publication bias.Cannabinoid type-1 receptor signaling in central serotonergic neurons regulates anxiety-like behavior and sociabilityDefining treatment response and symptom remission for anxiety disorders in pediatric autism spectrum disorders using the Pediatric Anxiety Rating Scale.TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROMEGlutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.Translational approaches to the biology of Autism: false dawn or a new era?Focal brain inflammation and autism.Anxiety in youth with autism spectrum disorders: implications for treatmentTreatment of comorbid anxiety and autism spectrum disordersPrefrontal activation during inhibitory control measured by near-infrared spectroscopy for differentiating between autism spectrum disorders and attention deficit hyperactivity disorder in adults.Prescription Drug Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism: A Retrospective Cross-Sectional AnalysisTreatment for co-occurring attention deficit/hyperactivity disorder and autism spectrum disorderSerotonin hypothesis of autism: implications for selective serotonin reuptake inhibitor use during pregnancy.Aripiprazole: a review of its use in the treatment of irritability associated with autistic disorder patients aged 6-17.Perspectives on the use of stem cells for autism treatmentAutism in context 2: Assessment, intervention and services in Australia.What's in the pipeline? Drugs in development for autism spectrum disorder.Multidisciplinary assessment and treatment of self-injurious behavior in autism spectrum disorder and intellectual disability: integration of psychological and biological theory and approach.Aripiprazole Improved Obsessive Compulsive Symptoms in Asperger's Disorder.What Have Proteomic Studies Taught Us About Novel Drug Targets in Autism?Intermittent theta-burst transcranial magnetic stimulation for autism spectrum disorder: an open-label pilot study.
P2860
Q21285056-50E95AD1-E33A-4CC8-846A-515AB98B6D41Q24194593-5395623B-FB98-4E6F-8232-29C6954631B7Q24200368-D521295F-1F91-42C2-9411-A1FD144D7749Q24201281-2F1B7058-A16E-46E3-992C-9722E8C8EBE4Q24201426-265FE393-049A-44AB-B665-423EF3BAEB4FQ24235241-F9810AA4-6A2C-4AE7-864C-0D87EA90E595Q26830626-D9345D25-1E9F-41B6-8F8C-381E3E5E7A6EQ27015716-77025995-B305-4D21-BD03-E496242BC1E7Q27023264-AFA6A0E8-72CB-4126-A51A-F8C90598503CQ27498709-B41FDCBB-9D24-4227-BD5E-36E962213199Q34270618-A0E30EE7-07B4-48DE-AD49-50CF8B2775C5Q34580758-9D38F02B-8D17-47CA-86FE-F5EE54594E8FQ35061750-802EC824-A222-4FB6-BC16-AA84B96F3451Q35151007-2464D1D8-9386-4FC2-86B2-9A0679C70D14Q35619221-CDD1E2B9-10A5-4ECF-B40B-8DB317B3308EQ35693662-41FE28E7-C832-4865-A3AC-ED122612003DQ35923595-FAAFB963-E270-4132-92CB-31C23D83913BQ36023651-0A62C446-CEE2-448F-AB90-D44A6ADF61CBQ36071385-C81E6AE3-3E1F-4207-B4DC-0E9B298A2FBEQ36399716-54245BF6-6A30-4EDA-A404-AB9FC948CC84Q36694513-9DAD8EF9-BF2D-4760-8D15-B71CF80E090CQ36712349-CF32A1B8-CF81-4EC4-BEA3-5C26DB90738CQ36766675-7BFFE9E4-C6B9-4635-8E1C-BCBFFE0D306FQ36951100-6A5B4227-8337-493A-965E-9BC81B1FA23EQ37257081-F014BAEB-E707-47C1-8EC1-D5013E845F96Q37347460-7FE8C9EC-BA0D-4A2E-8573-1F7F53EDA089Q37452761-B1D0269B-B01E-4AEA-A0FD-75DB76E9FBB0Q38017121-26F2A49A-1C1F-4169-80DF-32F316DA6481Q38089714-10946186-98BE-4CE7-8AEC-918FC2A6D592Q38122151-81E1CE25-3CEB-4346-8F3D-36238CED14A0Q38162181-1CF49BC5-1EDC-43C9-A291-23D17ED6F02FQ38178312-81022490-9F59-4278-BD23-4BA77B97C8DEQ38193069-AE0F10AF-F09A-4566-A5CF-1D0533ED9826Q38268023-2DD2645E-8CD2-477E-A46E-ACFD10271B5CQ43235601-46DBB09B-E2BA-4B54-8220-6D8EF9D71B5DQ47812079-4632DE61-3EBB-490A-8277-8CDE6C9751FFQ50147840-B0B55461-DF6B-43B5-8467-F59C0B882EDB
P2860
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
@ast
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
@en
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
@en-gb
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
@nl
type
label
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
@ast
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
@en
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
@en-gb
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
@nl
prefLabel
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
@ast
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
@en
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
@en-gb
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
@nl
P2093
P2860
P921
P1476
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
@en
P2093
Danielle M Wheeler
Katrina Williams
Natalie Silove
P2860
P304
P356
10.1002/14651858.CD004677.PUB2
P407
P577
2010-08-04T00:00:00Z